Stock Events

Stock Events

Moleculin Biotech 

0
85
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19AugExpected
Q1 2026
Next
-3.05
-2.5
-1.95
-1.41
Expected EPS
-1.4088850499999999
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-29.11MNet Income

Analyst Ratings

16.69Average Price Target
The highest estimate is 16.69.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MOL.STU. It's not an investment recommendation.
NVIDIA
14
NVDA
Apple
12
AAPL
AMD
11
AMD
Realty Income
10
O

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences is a biopharmaceutical company that develops and markets drugs in areas similar to Moleculin, including cancer, making it a direct competitor.
AMGEN
AMGN
Mkt Cap196.12B
Amgen focuses on human therapeutics, including treatments for cancer, which competes with Moleculin's cancer drug development efforts.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines for cancer, directly competing with Moleculin's oncology focus.
Merck
MRK
Mkt Cap305.12B
Merck operates in the pharmaceutical industry with a strong emphasis on cancer drugs, competing with Moleculin's product pipeline.
Pfizer
PFE
Mkt Cap137.76B
Pfizer is a global biopharmaceutical company with a broad range of drugs, including cancer treatments that compete with Moleculin's developments.
Novartis
NVS
Mkt Cap293.94B
Novartis is a healthcare company that offers treatments for a variety of conditions, including cancer, making it a competitor to Moleculin.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie is a research-based biopharmaceutical company with a strong emphasis on oncology, directly competing with Moleculin's focus areas.
Lilly(Eli) &
LLY
Mkt Cap1.06T
Eli Lilly is a global healthcare leader that develops drugs for cancer among other diseases, positioning it as a competitor to Moleculin.
Astrazeneca
AZN
Mkt Cap266.15B
AstraZeneca is a multinational pharmaceutical and biopharmaceutical company with a significant focus on oncology, competing with Moleculin.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals is known for its innovative medicines and therapeutic advancements, including in oncology, making it a competitor to Moleculin.

About

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Show more...
CEO
Mr. Walter V. Klemp
Employees
17
Country
United States
ISIN
US60855D1019

Listings

STU
DE
MOL.STU
LSE
GB
0K2H.LSE
MU
DE
MOL0.MU
BOATS
BOATS
MBRX.BOATS

0 Comments

Share your thoughts

FAQ

What is Moleculin Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Moleculin Biotech stocks are traded under the ticker MOL.STU.
When is the next Moleculin Biotech earnings date?▼
Moleculin Biotech is going to release the next earnings report on August 19, 2026.
What were Moleculin Biotech earnings last quarter?▼
MOL.STU earnings for the last quarter are -3.05 EUR per share, whereas the estimation was -2.01 EUR resulting in a -51.71% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Moleculin Biotech revenue for the last year?▼
Moleculin Biotech revenue for the last year amounts to 0 EUR.
What is Moleculin Biotech net income for the last year?▼
MOL.STU net income for the last year is -29.11M EUR.
How many employees does Moleculin Biotech have?▼
As of July 27, 2026, the company has 17 employees.
In which sector is Moleculin Biotech located?▼
Moleculin Biotech operates in the Other sector.
When did Moleculin Biotech complete a stock split?▼
The last stock split for Moleculin Biotech was on February 01, 2021 with a ratio of 1:6.
Where is Moleculin Biotech headquartered?▼
Moleculin Biotech is headquartered in Houston, United States.